Results 221 to 230 of about 4,586,589 (282)

Why frailty must be central in anti-amyloid therapies for Alzheimer’s disease

The Journal of nutrition, health and aging
openaire   +2 more sources

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

Brain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero‐Murillo, Djordje Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría   +7 more
wiley   +1 more source

Protective role of Galectin‐3 in prion disease through regulation of microglial PrPSc uptake

Brain Pathology, EarlyView.
Galectin‐3 (Gal3) is induced in reactive microglia during prion disease and promotes microglial uptake of PrPSc. Gal3 deficiency reduces prion sequestration and accelerates disease progression, revealing a protective role for Gal3. Abstract Microglia constitute a major innate defense mechanism against prion infection; however, the molecular pathways ...
Natallia Makarava, Tarek Safadi, Narayan P. Pandit, Olga Mychko, Olga Bocharova, Alexey Shevelkin, Kara Molesworth, Marta M. Lipinski, Ilia V. Baskakov   +8 more
wiley   +1 more source

Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable. [PDF]

J Prev Alzheimers Dis
Farrar G, Weber CJ, Rabinovici GD.
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Rifaximin ameliorates memory impairment and Alzheimer's pathological changes in APP/PS1 mice associated with changes in the gut microbiome–bile acids–serum metabolites networks

British Journal of Pharmacology, EarlyView.
Background and Purpose Modifying the brain–gut–microbiota axis has emerged as a promising therapeutic strategy against Alzheimer's disease (AD). Whether rifaximin, a non‐absorbed and non‐systemic antibiotic, can be applied to the treatment of AD remains unexplored.
Di Wu, Mei‐Tong Nie, Jixian Lin, Yang Liu, Yong Wang, Min Chu, Lan Zheng, Jing Zhao   +7 more
wiley   +1 more source

Improving the Delivery of Brain Health Care to All. Keeping our Eye on the Main Prize in an Era of Emerging Anti-Amyloid Therapies

Canadian Geriatrics Journal
Manuel Montero-Odasso, Linda Lee, David B. Hogan   +2 more
doaj  

A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer's Disease in Asia. [PDF]

J Alzheimers Dis
Lee JH, Jia J, Ji Y, Kandiah N, Kim S, Mok V, Pai MC, Senanarong V, Suh CH, Chen C.   +9 more
europepmc   +1 more source